Endometrioid Adenocarcinoma

10 clinical trials · Condition

Record	Firm	Date
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (NCT05112601)	National Cancer Institute (NCI)	2022-06-02
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) (NCT05001282)	Elucida Oncology	2021-09-13
Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus. (NCT04458597)	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	2020-08-26
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease (NCT04291612)	Memorial Sloan Kettering Cancer Center	2020-02-26
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) (NCT03824704)	pharmaand GmbH	2019-08-23
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers (NCT03748186)	Sutro Biopharma, Inc.	2019-02-01
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone (NCT03660826)	National Cancer Institute (NCI)	2018-09-27
Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers (NCT03345784)	National Cancer Institute (NCI)	2018-05-29
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (NCT02834013)	National Cancer Institute (NCI)	2017-01-30
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer (NCT01440998)	National Cancer Institute (NCI)	2011-09-20

Track Endometrioid Adenocarcinoma automatically

Every clearance here is in the API, with alerts when new ones post.